On Invalid Date, Aerovate Therapeutics (NASDAQ: AVTE) reported Q3 2022 earnings per share (EPS) of -$0.56, up 115.38% year over year. Total Aerovate Therapeutics earnings for the quarter were -$13.59 million. In the same quarter last year, Aerovate Therapeutics's earnings per share (EPS) was -$0.26.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.